Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
- PMID: 20006859
- DOI: 10.1016/j.juro.2009.10.022
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
Abstract
Purpose: Undetected cancer in repeat transrectal ultrasound guided prostate biopsies in patients with increased prostate specific antigen greater than 4 ng/ml is a considerable concern. We investigated the tumor detection rate of tumor suspicious regions on multimodal 3 Tesla magnetic resonance imaging and subsequent magnetic resonance imaging guided biopsy in 68 men with repeat negative transrectal ultrasound guided prostate biopsies. We compared results to those in a matched transrectal ultrasound guided prostate biopsy population. Also, we determined the clinical significance of detected tumors.
Materials and methods: A total of 71 consecutive patients with prostate specific antigen greater than 4 ng/ml and 2 or greater negative transrectal ultrasound guided prostate biopsy sessions underwent multimodal 3 Tesla magnetic resonance imaging. In 68 patients this was followed by magnetic resonance imaging guided biopsy directed toward tumor suspicious regions. A matched multisession transrectal ultrasound guided prostate biopsy population from our institutional database was used for comparison. The clinical significance of detected tumors was established using accepted criteria, including prostate specific antigen, Gleason grade, stage and tumor volume.
Results: The tumor detection rate of multimodal 3 Tesla magnetic resonance imaging guided biopsy was 59% (40 of 68 cases) using a median of 4 cores. The tumor detection rate was significantly higher than that of transrectal ultrasound guided prostate biopsy in all patient subgroups (p <0.01) except in those with prostate specific antigen greater than 20 ng/ml, prostate volume greater than 65 cc and prostate specific antigen density greater than 0.5 ng/ml/cc, in which similar rates were achieved. Of the 40 patients with identified tumors 37 (93%) were considered highly likely to harbor clinically significant disease.
Conclusions: Multimodal magnetic resonance imaging is an effective technique to localize prostate cancer. Magnetic resonance imaging guided biopsy of tumor suspicious regions is an accurate method to detect clinically significant prostate cancer in men with repeat negative biopsies and increased prostate specific antigen.
Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2010 Feb;183(2):527-8; discussion 528. doi: 10.1016/j.juro.2009.10.095. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006885 No abstract available.
-
Re: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.Eur Urol. 2011 Jul;60(1):178. doi: 10.1016/j.eururo.2011.04.015. Eur Urol. 2011. PMID: 21640693 No abstract available.
Similar articles
-
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19. J Urol. 2013. PMID: 23608676 Clinical Trial.
-
Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.J Urol. 2014 Nov;192(5):1374-9. doi: 10.1016/j.juro.2014.05.090. Epub 2014 May 24. J Urol. 2014. PMID: 24866597 Clinical Trial.
-
Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.NMR Biomed. 2007 Feb;20(1):11-20. doi: 10.1002/nbm.1083. NMR Biomed. 2007. PMID: 16894640
-
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.J Urol. 2001 Sep;166(3):856-60. J Urol. 2001. PMID: 11490233 Review.
-
[Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].Urologe A. 2003 Sep;42(9):1188-95. doi: 10.1007/s00120-003-0422-4. Urologe A. 2003. PMID: 14504751 Review. German.
Cited by
-
The emerging role of diffusion-weighted MRI in prostate cancer management.Nat Rev Urol. 2012 Jan 17;9(2):94-101. doi: 10.1038/nrurol.2011.222. Nat Rev Urol. 2012. PMID: 22249194 Review.
-
Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.World J Urol. 2014 Apr;32(2):461-7. doi: 10.1007/s00345-013-1130-3. Epub 2013 Jul 20. World J Urol. 2014. PMID: 23873356
-
Integrating multiparametric prostate MRI into clinical practice.Cancer Imaging. 2011 Oct 3;11 Spec No A(1A):S27-37. doi: 10.1102/1470-7330.2011.9007. Cancer Imaging. 2011. PMID: 22187067 Free PMC article. Review.
-
ESUR prostate MR guidelines 2012.Eur Radiol. 2012 Apr;22(4):746-57. doi: 10.1007/s00330-011-2377-y. Epub 2012 Feb 10. Eur Radiol. 2012. PMID: 22322308 Free PMC article.
-
Cognitive-Targeted versus Magnetic Resonance Imaging-Guided Prostate Biopsy in Prostate Cancer Detection.Curr Urol. 2018 Jun;11(4):182-188. doi: 10.1159/000447216. Epub 2018 Mar 30. Curr Urol. 2018. PMID: 29997460 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical